Honeywell

Phase A — Understand the business

Lens 1 · Company Overview

Honeywell is "an integrated operating company" — a multi-industry industrial that "blends physical products with software," run on its Honeywell Accelerator operating system and Honeywell Forge IoT/analytics platform. The brand dates to 1906; incorporated in Delaware 1985; HQ Charlotte, NC. FY2025 (Dec) revenue $37,442M, net income attributable to Honeywell $4,729M, ~635.3M shares out at year-end.

The business is being deliberately dismantled into three. Catalyzed by Elliott Management's >$5B activist stake (Nov 2024), which argued the conglomerate structure had caused ~6 years of peer underperformance:

1. Solstice Advanced Materials — spun off Oct 30, 2025 (now a separate public co); reported as discontinued operations.
2. Honeywell Aerospace (HONA) — spins June 29, 2026; ~$17.5B revenue, tier-1 aerospace & defense supplier.
3. Honeywell Technologies (HON RemainCo) — pure-play automation: Building Automation + Industrial Automation + Process Automation & Technology; 2026 outlook ~$19.9–20.2B sales.

Plus two clean-up sales: Productivity Solutions & Services (PSS) and Warehouse & Workflow Solutions (W&WS) — agreements signed April 2026, two transactions, closing 2H 2026.

As-reported FY2025 segments (legacy four-segment view):

Contract structure differs sharply by arm: Aerospace is long-cycle (OEM + a high-margin, sticky aftermarket — Commercial Aviation Aftermarket alone is $7,777M) plus cost-plus/fixed-price Defense & Space ($7,220M, exposed to US appropriations and shutdown risk). Automation (BA/IA/ESS) is shorter-cycle product + project + services. The installed-base + aftermarket model is the recurring-revenue spine across both.

Lens 2 · Supply Chain

Upstream inputs → Honeywell → end customer, named where the filings name them:

• Raw materials. Aerospace consumes nickel, steel, titanium and other metals; Energy & Sustainability/Process consumes copper, tungsten salts, aluminum, molybdenum. Chokepoint: "Many major components… and raw materials, particularly in Aerospace Technologies, are procured or subcontracted on a single or sole-source basis" — the explicit supply-chain risk. Mitigant: as of Dec 31 2025 the majority of Aerospace + ESS raw-material supply was under contract (formula-driven / long-term fixed-price / hedged).
• Manufacturing. ~$986M FY25 capex; 2026 guided ~$1.3B for "growth, production and capacity expansion".
• Downstream / customers (named). Aerospace sells to OEMs and operators — the 10-K cites a Q4-2024 strategic agreement with Bombardier (avionics, propulsion, satcom), and the US government / defense primes for Defense & Space. End markets: commercial air transport, business aviation, airlines, defense & space primes. Automation customers span refiners/petrochemical (UOP process licensing), building owners/contractors, and industrial/process plants.
• Geographic origin of supply/sales. US $21,784M (58%), Europe $8,112M (22%), Other international $7,546M (20%); >half of sales are international, US exports alone $7,895M. Tariff/trade-war exposure is explicitly flagged as potentially material.

Verdict on this lens: sole-source dependency in Aerospace is the real chokepoint; the rest is a well-diversified, contract-covered industrial supply base.

Lens 3 · Competitive Advantages (moats)

• Installed base + certified aftermarket (Aerospace). The deepest moat. Avionics, APUs, propulsion and engine controls are certified onto airframes — switching means re-certification. The $7.8B Commercial Aviation Aftermarket rides a global fleet for decades. This is the GE-Aerospace/RTX-class razor-and-blade model.
• Process IP / licensing (UOP). UOP licenses refining & petrochemical process technology + catalysts — a high-margin (22% segment), reference-installed-base moat. The Johnson Matthey Catalyst Technologies bolt-on (signed May 2025) deepens it.
• Switching costs in automation. Building & process control systems (Forge, Experion) are embedded in mission-critical operations; rip-and-replace risk for the customer = pricing power for Honeywell.
• Brand + scale (1906 brand; $37B revenue; global footprint).
• The bargaining-power asymmetry cuts both ways. Honeywell has power over fragmented building/industrial customers; it has less power against single-source aerospace suppliers (it needs them) and against the US government as a defense buyer (termination-for-convenience, audits).

Bottleneck note (commercial layer kb/robotics/wiki/positioning.md is robotics-scoped and only marginally relevant to this conglomerate; moats above are derived from the filings).

Lens 4 · Segments

Hard-sourced from the 10-K product/service and geographic disaggregation:

By product line within segment (FY25 sales):

• Aerospace: Commercial OE $2,513M · Commercial Aftermarket $7,777M · Defense & Space $7,220M.
• Industrial Automation: Sensing & Safety $1,171M (PPE divested May 2025) · PSS $1,132M (being sold) · Process Solutions $6,165M · W&WS $933M (being sold).
• Building Automation: Products $4,480M · Building Solutions $2,887M.
• ESS: UOP $3,134M.

Trend & cause:

• Aerospace accelerating (+13% two years running; organic +12% in 2025) on aftermarket flight-hours + Defense & Space shipments + CAES/Civitanavi acquisitions. The growth engine — and exactly why it commands the spin.
• Industrial Automation decelerating/shrinking (−6%; organic flat) — entirely portfolio surgery (PPE sale, W&WS/PSS held-for-sale). The "fix-it" segment.
• Building Automation strong (+13%, +8% organic; 26.5% margin — highest margin segment) on Access Solutions M&A + demand.
• ESS (+19% but organic −1%, organic profit −19%) — growth is entirely inorganic (LNG/Air Products, Sundyne). A flag: strip the acquisitions and ESS is shrinking.

New 5-segment structure as of Q1 2026 (pre-positioning the breakup): Aerospace, Building Automation, Process Automation & Technology (UOP + Process Solutions + Sundyne + JM Catalyst), Industrial Automation (shrunk), ESS folded in. Q1-26 Process Automation & Technology: $1,513M sales, $359M profit, 23.7% margin (+200bps); Industrial Automation: $1,421M, $241M, 17.0% margin (+260bps) — margin expansion is the RemainCo story.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print — Q1 2026, reported 2026-04-23)

GAAP, from the 10-Q:

• Net sales $9,143M vs $8,925M (+2.4% reported). Beat? Missed the Street top line by ~$140M.
• Continuing-ops diluted EPS $1.29 vs $1.97 prior-year quarter — a steep GAAP drop, but almost entirely one-timers: Impairment of assets held for sale $263M (PSS/W&WS), Loss on debt extinguishment $239M (pre-separation refi), R&D +$76M, interest +$71M, and a tough comp (PY had +$229M Other income). NCI swing (Quantinuum loss) −$26M.
• Non-GAAP/adjusted EPS $2.45, beat by $0.13. Segment margin 23.3% (+90bps); segment profit +6% on +2% sales — the operating engine is fine; the GAAP line is breakup noise.
• Market reaction: stock −5% intraday to ~$209 — punished for the revenue miss + cautious near-term tone, not the (strong) margins.
• Balance-sheet flags (Q1): total borrowings $36.7B (up from $34.6B at YE25); operating cash flow turned negative in the quarter on the $375M Flexjet settlement payment + $463M cash interest. A massive $15,835M pre-separation funding raised for the Aerospace spin, offset by $12.6B debt repayment — the balance sheet is being torn apart and re-assembled around the two cos.

FY2025 full-year context:

• Revenue $37,442M (+8%); gross margin 36.9% (−160bps YoY — mix + acquisition dilution + Flexjet).
• Operating income (revised) $5,573M, operating margin 14.9%; goodwill impairment $724M→$1,160M after a subsequent-event top-up of $436M (PSS/W&WS held-for-sale write-down).
• Continuing-ops diluted EPS $6.94 (flat YoY); total diluted EPS $7.36 (vs $8.71 in 2024 — the drop is impairments + divestiture costs + interest, partly offset by a $1.22 Resideo termination gain).
• Note the GAAP↔non-GAAP gap: management's 2026 guide is $9.59–$9.89 GAAP continuing diluted vs $10.35–$10.65 adjusted. Always specify which.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the shelf (transcripts=0); web-sourced. The tonal arc across the last ~4 calls:

• Late-2024 → early-2025: defensive/under-pressure (Elliott just public; "the conglomerate structure no longer suits us" was effectively conceded Feb 6 2025).
• Through 2025: the language pivots hard to "portfolio transformation," "value creation," "two world-class independent companies." Management stopped defending the conglomerate and started selling the breakup.
• Q1 2026 call: confident on margin + EPS, explicitly reaffirming (not raising) FY guide, leaning into "high-margin automation" and the imminent spin; acknowledged supply-chain constraints and soft near-term revenue.
• Recurring new phrases: Accelerator operating system, segment-margin expansion, separation on track for Q3. Dropped: conglomerate-synergy talk.

Lens 7 · Comps

HON's own multiple: price ~$227–228 (June 22 2026), market cap ~$149B, forward P/E ~21.3x. Peer table — multiples are ``, June 2026:

The SOTP read: HON at ~21x sits below every automation pure-play except Emerson and well below aerospace pure-plays. Post-spin, HONA (aerospace, ~$17.5B rev, growing 13%) should re-rate toward the GE Aerospace/RTX band (23–37x); HON Technologies (automation, margins expanding 220–270bps to ~20%) should re-rate toward Emerson/Rockwell (20–31x). That gap is the entire Elliott thesis. (Caveat: HONA carries Defense & Space, which trades nearer RTX's 23x than GE's 37x; don't assume the top of the band.)

Lens 8 · Stock-Price Catalysts (what moves the stock)

Pattern over the cycle:

• The single biggest >5% move was structural, not operational: Nov 2024, the stock jumped on Elliott's $5B stake + breakup demand. Confirmation Feb 6 2025 (three-way split announced) was the re-rate trigger.
• Q1 2026 print: −5% on a revenue miss despite an EPS beat — the tape reacts to organic revenue and guidance, not headline EPS (which is impairment-noisy).
• Quantinuum IPO (June 4 2026) — a positive surprise: monetized the unit Elliott called a "distraction" (see Lens 9).
• Credit-rating actions (Feb–Mar 2026) pressured sentiment (see Lens 10).

Read: this name trades on (1) portfolio/structural events and (2) organic growth + segment margin — far more than on GAAP EPS. The defining catalyst (June 29 spin) is now days away and largely priced (consensus PT $246.67, Buy; range $245–293, explicitly SOTP-driven).

---

Phase C — Judge people & books

Lens 9 · Management

• CEO: Vimal Kapur — CEO since June 2023, Chairman since June 2024 (age 60). A ~27-year Honeywell insider (ran HBT, Performance Materials, was COO). Track record: he is the architect/executor of the breakup — arguably the largest value-unlock in Honeywell's modern history. The bet on him is that an operator-insider can land a clean tax-free separation; the risk is that a lifer was also the steward of the underperformance Elliott attacked.
• CFO: Michal Stepniak — since Feb 2025, internal (ex-Aerospace CFO). Continuity through the most complex finance event in the company's history (two balance sheets, $15.8B pre-sep funding).
• Segment CEOs: Jim Currier (Aerospace — will lead HONA), Billal Hammoud (Building Automation), Pete Lau (Industrial Automation, joined Oct 2025 from FARO), Jim Masso (Process Automation, Jan 2026), Ken West (ESS). A largely refreshed bench, several external hires into the automation arms — consistent with a RemainCo being re-tooled.
• Capital-allocation history: aggressive on both ends. FY25 returned $6.78B to holders ($3,804M buybacks + $2,976M dividends) while spending $2.2B on Sundyne, £1.8B→£1.325B on JM Catalyst (price cut Feb 2026 — a discipline tell), and divesting PPE ($1.2B), Bendix asbestos ($1.4B cash out for a clean exit + indemnity), and Solstice. Dividend raised 5% to $1.19/qtr ($4.76 annualized) — a Dividend-Aristocrat cadence. Buyback now throttled: only $679M left under the $10B 2023 authorization at Q1-26 (capital is being conserved for the separation).
• Quantinuum monetization (the Elliott rebuttal): Honeywell IPO'd Quantinuum June 4 2026 (Nasdaq: QNT), raising $1.68B at a ~$12.7B fully-diluted valuation; Honeywell retains ~48.1% voting. Quantinuum did only $30.9M revenue (2025) — Elliott called it a "distraction"; management turned it into a ~$6B paper stake. Strong capital-allocation mark.
• Red flags: none egregious. Comp/related-party items are routine; 10b5-1 plans disclosed normally; insider-transactions.csv not on the shelf (couldn't quantify ownership/skin-in-game beyond plan disclosures — open item).

Lens 10 · Forensic Red Flags

Regulatory (required sub-section):

• SEC: "No LR found" and "No AAER found" for Honeywell since 2021-06-23, verified via SEC EDGAR EFTS. Clean.
• Non-SEC: web search for FTC/DOJ/FDA/consent-decree/penalty surfaced no material recent enforcement action as of June 2026; the live legal items are environmental (legacy/predecessor sites — explicitly "potentially material") and commercial litigation (Flexjet) — disclosed, not enforcement.
• Item 3 / Legal Proceedings (own disclosure): the Flexjet matter dominated FY25 — Q4 settlement charges cut Aerospace sales/profit ~$310M/$370M; the $375M settlement was paid in Q1 2026. Q1-26 10-Q states "no matters requiring disclosure" of environmental sanctions >$300k.

Accounting risk flags (label every figure):

• Goodwill / held-for-sale impairments. $724M FY25 goodwill impairment, topped up +$436M as a subsequent event after the earnings release (PSS/W&WS). The need to revise the just-released number is a mild estimation-quality flag — though it's a held-for-sale mark, not core ops.
• Non-GAAP flattery. Adjusted EPS ($10.35–10.65 guide) runs ~$0.76 above GAAP continuing ($9.59–9.89) — the wedge is impairments, separation costs, and amortization. Material but disclosed and explicable by the breakup; watch that it normalizes post-spin.
• Earnings vs. cash divergence. FY25 net income $4.7B but operating cash flow $6.4B was flattered by the $1,590M Resideo one-time receipt and dinged by the $1,428M asbestos payment — both non-recurring; underlying OCF is lumpy this year. Q1-26 OCF went negative on Flexjet + interest. 2026 FCF guide $5.3–5.6B is the cleaner forward number.
• Leverage. Total borrowings $36.7B (Q1-26) vs ~$12.4B cash → net debt ~$24B. Commercial paper $5.9B + a $2.75B drawn term loan — short-dated funding ahead of the spin.
• Receivables factoring. Trade-receivable sales (off-balance-sheet) disclosed as "not material to overall liquidity" — standard, but a working-capital optics item to monitor.

Forensic verdict: clean by enforcement standards; the only real "noise" is the breakup itself — impairments, the non-GAAP wedge, and a lumpy cash year. No revenue-recognition or related-party smoke.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

Anchor (management guidance + consensus): FY2026 sales $38.8–39.8B, organic +3–6%, adjusted EPS $10.35–10.65 (cons $10.52), GAAP continuing diluted $9.59–9.89, FCF $5.3–5.6B.

The projection problem is that the entity changes on June 29. Post-spin the two pieces have their own initiated outlooks:

• Honeywell Technologies (HON RemainCo): 2026 sales $19.9–20.2B, organic +2–3%, adjusted EPS $3.95–4.15 (+22–28%), segment margin 19.8–20.3% (+220–270bps), FCF ~$2.0B.
• Honeywell Aerospace (HONA): ~$17.5B+ revenue, ~24–25% segment margin; standalone EPS not yet cleanly disclosed in these sources (Form 10 governs) — open item.

Three-year EPS path — pre-spin "as if still combined" basis (for continuity; every line labeled). Base off FY25 adjusted ≈ $9.x and the 2026 guide:

• FY2026 (base): $10.50 adjusted.
• FY2027: $11.6.
• FY2028: $12.7.
• Bull: FY28 ~$13.8.
• Bear: FY28 ~$11.0.

Caveat: once HON and HONA trade separately these blended figures are illustrative only; the real model is two sum-of-the-parts EPS streams valued on their own multiples (Lens 7). No forecast.ts created — unattended --watchlist run (skip the Brier log per SKILL).

Lens 12 · Bull vs Bear

Bull case. The breakup is a mechanical value-unlock: a 21x blended conglomerate splits into (a) a growing aerospace pure-play (HONA) that the market pays 23–37x for, and (b) an automation company expanding margins 220–270bps that earns a 20–31x multiple. Elliott pencilled up to 75% upside. Add: $5.3–5.6B FCF, a 5%-raised aristocrat dividend, a clean Quantinuum monetization (+$6B paper stake, optionality on a quantum leader), legacy liabilities (asbestos, Resideo) permanently retired in 2025, and aerospace aftermarket riding record flight hours.

Bear case (things that permanently impair or de-rate).

1. The catalyst is already in the price. Consensus PT $246.67 vs ~$227 spot = ~8% to target; the SOTP is the explicit basis of those targets. The breakup has already re-rated the stock toward fair value — you may be buying the rumour after it's news.
2. Standalone-cost dis-synergies + leverage. Two public companies carry duplicated corporate cost; net debt ~$24B is being split across them, and three rating agencies put HON on negative/review watch (Feb–Mar 2026). A downgrade raises the cost of capital for both successors.
3. Automation organic is soft. IA organic flat, ESS organic −1% (profit −19%) — strip M&A and the automation engine is barely growing; the RemainCo story leans heavily on margin expansion, which has a ceiling.

Pre-mortem (it's Dec 2027, thesis broke — what happened?): an industrial/PMI downturn hit short-cycle automation just as the two standalones were absorbing separation costs; HONA's defense aftermarket got tagged with appropriations delays; the SOTP re-rate never came because the sum traded at the parts (the discount was already gone by June 2026), and a rating downgrade lifted interest cost. Net: two fairly-valued mid-cyclicals instead of one cheap one.

Contrarian view of what the market refuses to see: the cleaner long here is HONA in isolation — a sticky-aftermarket aerospace pure-play that, once freed from the automation drag and the conglomerate discount, screens against GE Aerospace's 37–40x while only being asked to earn RTX's 23x. The market is treating June 29 as the finish line; for HONA it may be the starting line.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull:

• "Sum-of-the-parts" is the most over-rented trade on the Street. By the time a breakup is six days away and every PT is a published SOTP, the alpha is gone. You're left holding two ordinary industrials at full multiples.
• Where's the growth without the chequebook? FY25 segment growth was juiced by CAES, Civitanavi, Access Solutions, LNG, Sundyne. ESS organic −1%, IA organic flat. The "automation growth company" narrative is, organically, a low-single-digit grower dressed up by M&A and margin self-help.
• The balance sheet is the danger. $36.7B borrowings, ~$24B net debt, $5.9B commercial paper, a $2.75B term loan, three agencies on negative/review watch, all being cleaved in two. Separation finance can go wrong; standalone HONA and HON each inherit leverage with less diversification to service it.
• Most dangerous competitor bulls underrate: in automation, Emerson (post-AspenTech, focused, cheaper at 20x) and Rockwell; in aerospace, GE Aerospace + RTX with deeper engine franchises. A standalone HON Technologies is smaller than Emerson — sub-scale in a consolidating automation market.
• Capital-allocation skeletons? Not really — the JM Catalyst price cut and asbestos clean exit are good marks. The honest short is valuation + leverage + organic-growth quality, not fraud.
• What if growth disappoints 20–30%? If organic goes to ~0% in a downturn, adjusted EPS stalls near $10 and both successors de-rate to ~17–18x → meaningful downside from $227. The single permanent-impairment scenario is a rating downgrade into a recession that raises cost of capital while organic growth is absent — plausible but not base-case.

Lens 14 · Management Questions (ordered by information value)

1. Post-spin, what are HONA's and HON Technologies' standalone net-leverage targets and committed credit ratings, and how do you defend them against the current Moody's review-for-downgrade / S&P negative outlook?
2. Stripping all M&A, what is your honest 3-year organic growth assumption for the automation RemainCo — and what specifically reverses ESS's −1% / IA's flat organic?
3. What is the fully-loaded standalone-cost dis-synergy (duplicated corporate, IT, public-company costs) across the two companies, in dollars, and when does it normalize?
4. For HONA, what is the OE/aftermarket revenue mix and aftermarket growth durability if global flight hours plateau?
5. Quantinuum: with ~48.1% retained voting and a $12.7B IPO mark — is this a core holding, a monetization runway, or a future distribution to shareholders?
6. Where does the buyback restart post-spin, and at what pace, given only $679M was left under authorization at Q1-26?
7. How much of the 2026 adjusted-EPS guide depends on price vs. volume, and what is the tariff/trade-war sensitivity given >half of sales are international?
8. What recurring/software revenue (Forge) is embedded in each successor, and what is its growth + margin vs. the hardware base?
9. Defense & Space: what is the exposure to a US government shutdown / appropriations slip, and how much revenue is cost-plus vs. fixed-price?
10. What is the post-spin capital-allocation framework for each company — dividend payout target, M&A appetite, ROIC hurdle?
11. JM Catalyst closed at £1.325B (down from £1.8B): what changed in diligence, and what's the integration/synergy plan inside Process Automation?
12. What residual environmental / legacy liability stays with HON vs. transfers to HONA/Solstice, and what's the worst-case reasonably-possible exposure?
13. How will management incentives be structured at the two standalones to align with the SOTP value-creation thesis?
14. What is the single internal metric the board will use to judge whether the breakup worked two years out?
15. If the SOTP re-rate doesn't materialize within 12 months of the spin, what is the next lever?

---